The American Journal of Managed Care12 天
Targeted Therapy in CLL May Impact Blood Cell Behavior
Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...